Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663014 | 0.88 | AKR1C3 (0.60) | KDM4EAKR1C3AKR1C2KMT2AMEN1 | |
| SCHEMBL7149329 | 0.83 | KDM4E (0.54) | KDM4EHSD17B10GAAGLAPOLB | |
| SCHEMBL27969573 | 0.82 | KDM4E (0.49) | KDM4EHSD17B10GAAGLAPOLB | |
| SCHEMBL4070159 | 0.82 | KDM4E (0.71) | KDM4EGAAALDH1A1HPGDKMT2A | |
| SCHEMBL4013508 | 0.81 | GAA (0.56) | KDM4EGAAKMT2AMEN1MAPT | |
| SCHEMBL30981444 | 0.81 | TRIM24 (0.51) | KDM4EGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL17084899 | 0.81 | TRIM24 (0.51) | KDM4EGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL30076369 | 0.80 | ALDH1A1 (0.47) | KDM4EGAAPOLBALDH1A1HPGD | |
| SCHEMBL5226002 | 0.80 | TDP1 (0.54) | KDM4EGAACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1234368 | 0.80 | ALDH1A1 (0.47) | KDM4EGAAPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733299-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Braegen Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-20240400562-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024240186-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳博芮健制药有限公司 | 2024-11-28 | — | — | WO | disclosed |
| EP-4419509-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118339149-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023066359-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400562-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR6 | KDM4E 4584/4885HSD17B10 1033/4885GAA 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.